---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-021614"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:56:30.137148+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma Q2 net loss $4.5M; launches Phase 2 Harmonic trial for LP-300 in never-smoker NSCLC

## Summary
- Net loss of $4.5M ($0.41 per share) vs $2.3M ($0.21) in Q2 2021; R&D spend increased to $3.0M from $1.2M.
- Cash, cash equivalents, and marketable securities $62.2M as of June 30, 2022, down from $79.6M a year ago; cash runway into 2025.
- Phase 2 Harmonic trial for LP-300 launched; enrollment begins Q3 2022; initial results expected Q4 2023.
- INDs for LP-184 and LP-284 planned for early 2023; Phase 1 trials for LP-184 (CNS + solid tumors) and LP-284 (NHL) anticipated in H1 2023.
- RADR platform now exceeds 21 billion data points; Dr. Maria Maccecchini elected to board of directors.

## SEC filing metadata
- accession: 0001493152-22-021614
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000149315222021614/0001493152-22-021614-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000149315222021614/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-021614
- JSON: https://secwatch.observer/filing/0001493152-22-021614.json
- Plain text: https://secwatch.observer/filing/0001493152-22-021614.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.